Tumor‐Derived Extracellular Vesicles in Plasma for Predicting Anti‐ PD ‐1 Antibody Efficacy in Non‐Small Cell Lung Cancer
Open Access
- 24 May 2026
- journal article
- Published by Wiley in Cancer Science
- Vol. 117 (8) , 2152-2165
Abstract
Liquid biopsy is a promising biomarker for cancer detection and prediction of therapy responses. In this study, we developed new antibody‐based sandwich assays to measure three extracellular vesicle (EV) subsets that express cell surface vimentin (CSV) and co‐express epithelial cell adhesion molecule (EpCAM) or PD‐L1 in plasma. Fifty‐seven non‐small cell lung cancer (NSCLC) patients who underwent complete resection and 89 stage IV NSCLC patients who received anti‐PD‐1 antibody were enrolled. Correlations between the plasma EV subsets at baseline and various clinicopathological factors were evaluated. Plasma EpCAM/CSV‐EV levels were significantly higher in stage I NSCLC patients compared to healthy donors, suggesting this may be a valuable biomarker for detecting early‐stage NSCLC. High plasma CSV/CSV‐EV levels at baseline were significantly correlated with a poor prognosis after treatment, both in the surgery cohort and the anti‐PD‐1 antibody cohort, which suggests that this may be useful for predicting the post‐treatment prognosis in NSCLC patients. High plasma CSV/PD‐L1‐EV levels at baseline were significantly correlated with poor postoperative prognosis. However, high plasma CSV/PD‐L1‐EV levels at baseline were significantly correlated with a favorable clinical response and prognosis following anti‐PD‐1 antibody treatment in stage IV NSCLC. Therefore, plasma CSV‐related EV subsets at baseline may be attractive biomarkers for early cancer detection (EpCAM/CSV), prediction of postoperative prognosis (CSV/CSV), and prediction of clinical responses and prognosis after anti‐PD‐1 antibody therapy (CSV/PD‐L1). These EV subsets can be easily measured repetitively at appropriate timing. These novel liquid biopsies may be additional and complementary diagnostic biomarkers for NSCLC patients.Keywords
Funding Information
- Japan Agency for Medical Research and Development (16cm0106305h0001)
- Japan Agency for Medical Research and Development (25be0904018j0002)
This publication has 21 references indexed in Scilit:
- Exosomal PD-L1 predicts response with immunotherapy in NSCLC patientsClinical and Experimental Immunology, 2022
- Unbiased peptoid cell screen identifies a peptoid targeting newly appeared cell surface vimentin on tumor transformed early lung cancer cellsBioorganic & Medicinal Chemistry, 2022
- The Pandora’s box of novel technologies that may revolutionize lung cancerLung Cancer, 2021
- The clinical significance of soluble PD-1 and PD-L1 in lung cancerCritical Reviews in Oncology/Hematology, 2019
- Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumabOncoImmunology, 2018
- PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLCBritish Journal of Cancer, 2018
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- Forkhead box P3 regulatory T cells coexisting with cancer associated fibroblasts are correlated with a poor outcome in lung adenocarcinomaCancer Science, 2013
- Cancer Metastasis Is Accelerated through Immunosuppression during Snail-Induced EMT of Cancer CellsCancer Cell, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009